Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
After 1 year of treatment over half had successful results, remission endpoint. Only 14% on placebo that's huge news! It works. Looking forward to moving forward.
Rinvoq meets_all_primary_and_secondary_endpts_in UC-maintenance phase-3:
https://finance.yahoo.com/news/upadacitinib-rinvoq-met-primary-secondary-120000332.html
Rinvoq FDA review in PA delayed (again) due to JAK-class safety issues:
https://finance.yahoo.com/news/abbvie-provides-regarding-rinvoq-upadacitinib-123000377.html
Another successful phase1 and completed acquisition.
https://www.biospace.com/article/abbvie-exercising-right-to-buy-teneoone-and-its-lead-multiple-myeloma-asset/
ABBV has been a good core holding to just accumulate dividends and get capital appreciation
A few years ago it was a buy. Now it's a strong buy!
https://www.fool.com/investing/2021/03/02/warren-buffett-and-cathie-wood-just-bought-this-ju/
ABBV—Rinvoq sBLA for atopic dermatitis extended three months for FDA to review additional data submitted during the review—new PDUFA is “late 3Q21”:
https://finance.yahoo.com/news/abbvie-announces-extension-review-supplemental-211800386.html
This is the second Rinvoq sBLA whose review was recently extended by the FDA—the other was the sBLA in psoriatic arthritis (#msg-162613514). In both cases, the FDA seems unsure about the risk/benefit tradeoff.
Bottom line: ABBV’s peak sales projection for Rinvoq may be too optimistic. ABBV has been saying that Rinvoq and Skyrizi combined will do $15B of annual sales by 2025.
I added too on that drop. Overreaction by the market, imo.
There are few high dividend pharmaceutical stocks out there. Great diversification add.
Nice. SVB upps target from 140 to 144
Atogepant for prevention of episodic migraine has PDUFA date in late 3Q21:
https://www.prnewswire.com/news-releases/us-fda-accepts-abbvies-new-drug-application-for-atogepant-for-the-preventive-treatment-of-migraine-301257758.html
This drug came from Allergan.
Nice add on the drop. I’m going to add to a core position here next week. It’s nice to have stocks like these in a balanced portfolio especially in a bit of an uncertain environment.
Picked up some more ABBV. Dividend is too sweet to ignore.
Rinvoq PDUFA date for psoriatic arthritis extended 3 months to “late 2Q21”:
https://finance.yahoo.com/news/abbvie-announces-extension-review-supplemental-124500090.html
$abbv $106.6 v -1.25 (-1.16%)
Volume: 7,218,576 @03/03/21 7:58:24 PM EST
$abbv $107.75 ^ 0.42 (0.39%)
Volume: 9,249,971 @02/26/21 7:58:44 PM EST
$abbv $104.47 ^ 0.72 (0.69%)
Volume: 3,725,009 @02/12/21 6:41:58 PM EST
ABBV pipeline update:
https://investors.abbvie.com/static-files/9c3dba8e-5447-4e55-a78f-d167a91b1e99
$abbv $111.0 v -1.62 (-1.44%)
Volume: 5,417,311 @01/21/21 7:41:26 PM EST
ABBV/AGN presentation_lineup_at “Toxins 2021” conference:
https://finance.yahoo.com/news/allergan-aesthetics-allergan-abbvie-company-140000028.html
Abstracts will be available online on 1/16/21.
ABBV takes option to acquire aesthetic-device company:
https://finance.yahoo.com/news/allergan-aesthetics-enters-option-acquire-210500724.html
Financial terms were not disclosed.
$abbv $107.15 ^ 1.88 (1.79%)
Volume: 6,148,110 @12/31/20 7:58:35 PM EST
$abbv $103.39 ^ 0.11 (0.11%)
Volume: 1,378,650 @12/24/20 5:00:00 PM EST
$abbv $104.99 ^ 0.95 (0.91%)
Volume: 5,490,541 @12/02/20 6:23:29 PM EST
$abbv $104.97 ^ 0.77 (0.74%)
Volume: 4,418,751 @11/27/20 5:00:00 PM EST
JUST IN: $ABBV Like Dividends? I Bet You'll Love These 3 Stocks
Investment fads come and go, and growth stories eventually end. Income-producing stocks always fit into a portfolio, however, even if those dividends are being collected to purchase other sorts of positions. And, given the uncertainty that lies in our immediate future, a little more certain...
In case you are interested ABBV - Like Dividends? I Bet You'll Love These 3 Stocks
$abbv $99.0 ^ 1.4 (1.43%)
Volume: 6,877,285 @11/13/20 4:41:03 PM EST
$abbv $85.11 ^ 4.44 (5.50%)
Volume: 18,095,186 @10/30/20 7:58:30 PM EDT
Just In: $ABBV 5 No-Brainer Stocks to Buy if Donald Trump Wins in November
Talking heads get paid to speculate about what the market will do in different scenarios, but it is rare that anyone can truly know how a particular company, industry, or the overall market will fare based on a presidential election. That said, a reelection of a U.S. President offers mo...
Got this from ABBV - 5 No-Brainer Stocks to Buy if Donald Trump Wins in November
Just In: $ABBV AbbVie (ABBV) Q3 2020 Earnings Call Transcript
Image source: The Motley Fool. AbbVie (NYSE: ABBV) Q3 2020 Earnings Call Oct 30, 2020 , 9:00 a.m. ET Operator Continue reading For further details see: AbbVie (ABBV) Q3 2020 Earnings Call Transcript
In case you are interested ABBV - AbbVie (ABBV) Q3 2020 Earnings Call Transcript
News; $ABBV How AbbVie Beat Expectations in Q3
AbbVie (NYSE: ABBV) hasn't exactly given investors a lot to get excited about so far in 2020. As of Thursday's close, its shares were down by 9% year to date, lagging well behind the S&P 500 index 's performance. However, the big drugmaker's shareholders now have a reaso...
In case you are interested ABBV - How AbbVie Beat Expectations in Q3
News; $ABBV AbbVie Reports Third-Quarter 2020 Financial Results
AbbVie Reports Third-Quarter 2020 Financial Results - Reports Third-Quarter Diluted EPS of $1.29 on a GAAP Basis; Adjusted Diluted EPS of $2.83 - Delivers Third-Quarter Net Revenues of $12.902 Billion on a GAAP Basis, an Increase of 52.1 Percent on a Reported Basis; Adjusted...
Read the whole news ABBV - AbbVie Reports Third-Quarter 2020 Financial Results
Breaking News: $ABBV 2 No-Brainer Dividend Stocks Yielding More Than 4%
For dividend-seeking investors, looking at a stock's yield is important. High yields tend to be more attractive than low yields if all other things remain equal. But in real life, things are rarely equal, so before purchasing shares of a company because of its dividend, it's essential to lo...
Got this from ABBV - 2 No-Brainer Dividend Stocks Yielding More Than 4%
AbbVie (NYSE:ABBV) declares $1.30/share quarterly dividend, 10.2% increase from prior dividend of $1.18.
Forward yield 6.45%
Payable Feb. 16; for shareholders of record Jan. 15; ex-div Jan. 14.
ABBV 3Q20 results—2020 guidance raised slightly:
https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-third-quarter-2020-financial-results
New 2020 non-GAAP EPS guidance is $10.47-10.49 (from prior range of $10.35-10.45).
ABBV phase-3 trials in presbyopia hit primary endpoint:
https://finance.yahoo.com/news/allergan-abbvie-company-announces-positive-120000680.html
Detailed data to be presented at an unspecified medical conference.
AGN-190584, a once-daily eye drop, was inherited from Allergan.
ABBV is in a low risk buying range, IMO.
Healthy dividend. "Healthy" sector.
$abbv $83.01 v -1.24 (-1.47%)
Volume: 9,746,011 @10/21/20 7:58:03 PM EDT
The Race To Treat Spinal Cord Injury is On: AbbVie pharmaceuticals $ABBV and RespireRx Pharmaceuticals Inc. (RSPI) on Watch https://dailytrendingstocks.com/the-race-to-treat-spinal-cord-injury-is-on-abbvie-pharmaceuticals-abbv-and-respirerx-pharmaceuticals-inc-rspi-on-watch/?source=push_monkey
JUST IN: $ABBV Got $5,000? Here Are 2 Dividend Growth Stocks to Buy and Hold for Decades
If you are in a financial position to invest $5,000 in new stocks today, you will find no shortage of exciting options. If you would like to balance the potential for solid returns with long-term stability, dividend stocks might be the best place to start your search. Companies that have a ...
Find out more ABBV - Got $5,000? Here Are 2 Dividend Growth Stocks to Buy and Hold for Decades
Followers
|
80
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
768
|
Created
|
12/08/12
|
Type
|
Free
|
Moderators DewDiligence |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |